Memantine Sandoz

Memantine, the active ingredient in Memantine Sandoz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It treats moderate to severe Alzheimer’s disease in adults, helping to improve cognition and daily functioning.

GNH USA supplies Memantine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine acts on the glutamatergic system and is indicated for Alzheimer’s disease and related cognitive disorders. - Alzheimer’s disease (moderate to severe): improves cognition, memory, and functional abilities. - Cognitive impairment due to Alzheimer’s disease: helps maintain daily activities. - Behavioral disturbances in Alzheimer’s disease: may reduce agitation and aggression.

Memantine is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Dizziness: mild to moderate vertigo or light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Seizures: rare convulsive episodes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes. - Psychosis: new or worsening hallucinations or delusions. - Suicidal thoughts: emergence of suicidal ideation.

Memantine should be used with caution in several clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use cautiously in patients with unstable heart conditions. - Pregnancy: safety not established; avoid unless clearly needed. - Concomitant NMDA antagonists: avoid combined use due to additive effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Memantine may interact with other medicines that affect the NMDA pathway or renal clearance.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Ketamine: additive NMDA blockade may lead to severe CNS effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - Diuretics: can alter renal excretion and affect drug concentration.